Understanding Open-Angle Glaucoma Moderate Stage diagnosis, clinical documentation, and medical coding? Find information on intraocular pressure, visual field loss, optic nerve damage, cup-to-disc ratio, gonioscopy, tonometry, and relevant ICD-10 codes like H40.11 for accurate healthcare records and billing. Learn about treatment options, management strategies, and disease progression for moderate open-angle glaucoma.
Also known as
Open-angle glaucoma, moderate stage
Moderate stage open-angle glaucoma affecting both eyes.
Open-angle glaucoma, moderate stage
Moderate stage open-angle glaucoma, unspecified eye.
Open-angle glaucoma, moderate stage
Moderate stage open-angle glaucoma affecting one eye.
Glaucoma
Group of eye conditions causing optic nerve damage.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the glaucoma open-angle?
When to use each related code
| Description |
|---|
| Open-angle glaucoma, moderate stage |
| Normal-tension glaucoma |
| Ocular hypertension |
Missing or unclear documentation of laterality (right, left, bilateral) for glaucoma impacts code selection (H40.11X, H40.12X).
Insufficient documentation to support moderate stage may lead to incorrect coding or downcoding, impacting reimbursement.
Discrepancies between exam findings and documented stage of glaucoma may trigger audits and require clarification.
Q: What are the most effective IOP-lowering strategies for managing moderate stage open-angle glaucoma in patients with documented progression despite current therapy?
A: Managing progressive moderate stage open-angle glaucoma despite existing therapy requires a multifaceted approach focused on maximizing IOP reduction. Consider implementing a combination therapy strategy, utilizing medications with different mechanisms of action such as prostaglandin analogs, beta-blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors, or rho-kinase inhibitors. Laser trabeculoplasty (SLT) can also be highly effective in this stage and may offer an alternative or adjunct to further medication increases. If medical and laser therapies are insufficient, minimally invasive glaucoma surgery (MIGS) procedures like iStent inject or goniotomy may be considered before traditional filtering surgery. The specific strategy should be individualized based on patient characteristics, medication tolerance, and the rate of disease progression. Explore how different MIGS procedures compare in terms of efficacy and safety profiles for moderate-stage open-angle glaucoma. Careful monitoring of IOP, visual fields, and optic nerve head changes is crucial to evaluate treatment success and guide further adjustments.
Q: How do I differentiate between normal-tension glaucoma and moderate stage open-angle glaucoma with fluctuating IOP in a patient experiencing visual field loss?
A: Differentiating between normal-tension glaucoma (NTG) and moderate stage open-angle glaucoma with fluctuating IOP can be challenging when both present with visual field loss. In NTG, IOP measurements consistently fall within the normal range, despite the presence of glaucomatous optic neuropathy and corresponding visual field defects. Patients with fluctuating IOP may have peaks that contribute to damage even if their average IOP seems normal. Thorough evaluation requires careful review of 24-hour IOP profiles, assessment of diurnal IOP fluctuations, and consideration of other risk factors like vascular dysregulation, nocturnal hypotension, and optic nerve head susceptibility. Imaging techniques such as optical coherence tomography (OCT) can help assess retinal nerve fiber layer (RNFL) thickness and optic nerve head parameters, providing further evidence to distinguish between the two conditions. Learn more about the role of OCT in differentiating glaucomatous optic neuropathy from other optic neuropathies. Additionally, consider implementing a comprehensive assessment of cardiovascular risk factors and nocturnal blood pressure monitoring in patients suspected of having NTG.
Patient presents with moderate stage open-angle glaucoma. The patient reports gradual peripheral vision loss and increased difficulty with night vision. Intraocular pressure (IOP) measurements were elevated in both eyes, right eye measuring 26 mmHg and left eye measuring 28 mmHg. Gonioscopy confirmed open anterior chamber angles bilaterally. Optic nerve head evaluation revealed moderate cupping with a cup-to-disc ratio of 0.7 in the right eye and 0.8 in the left eye. Visual field testing demonstrated characteristic glaucomatous defects consistent with moderate stage progression. The patient's medical history is significant for hypertension, well-controlled with medication. Family history is positive for glaucoma. Diagnosis of moderate open-angle glaucoma established based on elevated IOP, characteristic optic nerve damage, and corresponding visual field loss. Treatment plan includes initiation of topical prostaglandin analog therapy, latanoprost ophthalmic solution once daily in both eyes, to lower intraocular pressure. Patient education provided on glaucoma management, medication administration, and the importance of regular follow-up appointments for monitoring disease progression and treatment efficacy. Patient scheduled for follow-up visit in four weeks to reassess IOP and visual fields. ICD-10 code H40.11, moderate stage open-angle glaucoma, was assigned. Medical billing codes for ophthalmological examination, gonioscopy, and visual field testing were also documented.